Intellia Therapeutics Inc (NASDAQ:NTLA) Given Average Recommendation of “Buy” by Analysts
Intellia Therapeutics Inc (NASDAQ:NTLA) has received a consensus rating of “Buy” from the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $26.92.
NTLA has been the subject of several recent analyst reports. Zacks Investment Research downgraded Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 1st. Raymond James upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $24.00 price target for the company in a report on Friday, November 1st. Chardan Capital restated a “buy” rating and issued a $57.50 price target on shares of Intellia Therapeutics in a report on Thursday, January 9th. ValuEngine downgraded Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 5th. Finally, BidaskClub downgraded Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th.
Large investors have recently bought and sold shares of the stock. Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of Intellia Therapeutics by 226.6% in the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,239,737 shares of the company’s stock valued at $96,650,000 after buying an additional 5,023,077 shares during the last quarter. Nikko Asset Management Americas Inc. increased its stake in Intellia Therapeutics by 40.3% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 7,239,737 shares of the company’s stock worth $96,650,000 after acquiring an additional 2,078,639 shares during the period. Vanguard Group Inc. increased its stake in Intellia Therapeutics by 13.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,184,116 shares of the company’s stock worth $52,124,000 after acquiring an additional 371,724 shares during the period. BlackRock Inc. increased its stake in Intellia Therapeutics by 6.6% during the 2nd quarter. BlackRock Inc. now owns 3,390,267 shares of the company’s stock worth $55,499,000 after acquiring an additional 208,548 shares during the period. Finally, Renaissance Technologies LLC bought a new position in Intellia Therapeutics during the 2nd quarter worth $2,695,000. Institutional investors and hedge funds own 90.19% of the company’s stock.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.12. Intellia Therapeutics had a negative return on equity of 33.00% and a negative net margin of 225.54%. The company had revenue of $10.60 million during the quarter, compared to the consensus estimate of $9.17 million. During the same period in the prior year, the company earned ($0.53) earnings per share. The company’s revenue for the quarter was up 43.2% compared to the same quarter last year. Equities analysts expect that Intellia Therapeutics will post -2.06 EPS for the current year.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
See Also: What is Forex?
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.